Journals / Genel Tıp Dergisi / 2018 / Cilt: 28 - Sayı: 1

Sjögren sendromu tanısı ile takip edilirken, anti-fosfolipid antikor pozitifliğinin gelişimi ile sistemik lupus eritromatozis olarak değerlendirilen olgu

Pages
34–36
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We presented a 40-year-old woman who had been diagnosed with Sjögren's Syndrome for 5 years than developed anti-phospholipid antibody positivity, and was diagnosed as Systemic Lupus Erythematosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Clinically in connective tissue diseases may settle years after autoantibody positivity, and new autoantibody positivity may develop over time.
📊
Key Findings & Data:We presented a 40-year-old woman who had been diagnosed with Sjögren's Syndrome for 5 years than developed anti-phospholipid antibody positivity, and was diagnosed as Systemic Lupus Erythematosis. reason, it may be useful to repeat to evaluate all symptoms and signs of connective tissue diseases and repeat serology if necessary, following the patients.
💡
Conclusion & Impact:We presented a 40-year-old woman who had been diagnosed with Sjögren's Syndrome for 5 years than developed anti-phospholipid antibody positivity, and was diagnosed as Systemic Lupus Erythematosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Clinically in connective tissue diseases may settle years after autoantibody positivity, and new autoantibody positivity may develop over time. For this reason, it may be useful to repeat to evaluate all symptoms and signs of connective tissue diseases and repeat serology if necessary, following the patients. We presented a 40-year-old woman who had been diagnosed with Sjögren's Syndrome for 5 years than developed anti-phospholipid antibody positivity, and was diagnosed as Systemic Lupus Erythematosis. reason, it may be useful to repeat to evaluate all symptoms and signs of connective tissue diseases and repeat serology if necessary, following the patients. We presented a 40-year-old woman who had been diagnosed with Sjögren's Syndrome for 5 years than developed anti-phospholipid antibody positivity, and was diagnosed as Systemic Lupus Erythematosis.

Özet

Konnektif doku hastalıklarında klinik, otoantikor pozitifliğinden yıllar sonra yerleşebilir, zamanla yeni otoantikor pozitifliği gelişebilir. Bu nedenle hastaların takibinde konnektif doku hastalıklarının tüm semptom ve bulgularının tekrar gözden geçirilmesi ve gerekli görüldüğünde serolojinin tekrarlanması yararlı olabilir. Olgumuz 5 yıldır Sjögren Sendromu tanısı ile takip edilirken anti-fosfolipid antikor pozitifliği gelişmesi nedeniyle Sistemik Lupus Eritromatozis tanısı konulan 40 yaşında bir kadın hastadır. Anahtar Kelimeler: Sistemik Lupus Eritromatozis, Anti-Fosfolipid Antikor, Sjögren Sendromu Abstract Clinically in connective tissue diseases may settle years after autoantibody positivity, and new autoantibody positivity may develop over time. For Konnektif doku hastalıklarında klinik, otoantikor pozitifliğinden yıllar sonra yerleşebilir, zamanla yeni otoantikor pozitifliği gelişebilir. Bu nedenle hastaların takibinde konnektif doku hastalıklarının tüm semptom ve bulgularının tekrar gözden geçirilmesi ve gerekli görüldüğünde serolojinin tekrarlanması yararlı olabilir. Olgumuz 5 yıldır Sjögren Sendromu tanısı ile takip edilirken anti-fosfolipid antikor pozitifliği gelişmesi nedeniyle Sistemik Lupus Eritromatozis tanısı konulan 40 yaşında bir kadın hastadır.

🔖

Cite This Article

UĞUR, S., AYTEKİN, A. A., KAÇAR, C. (2018). Sjögren sendromu tanısı ile takip edilirken, anti-fosfolipid antikor pozitifliğinin gelişimi ile sistemik lupus eritromatozis olarak değerlendirilen olgu. Genel Tıp Dergisi, Cilt: 28 - Sayı: 1, 34–36. https://ajindex.com/articles/224819

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Cooper GS.Unravelling The Etiology of systemic autoimmunediseases: peeringintopreclinical of disease. J Rheumatol 2009;36:1853-5.
  2. Hochberg M, Silman A, Smolen J, Weinblatt M, Weisman M.Rheumatology 6th ed volüme 2.Philadelphia, 2015; 1328-30.
  3. Heinlein LD, McClain MT, Merrill J,et al. Clinicalcriteriaforsystemiclupuserythematosusprecedediagnosis, andassociatedautoantibodiesarepresentbeforeclinicalsymptoms. ArthritisRheum 2007;56:2344-51. EularTextbook on RheumaticDiseases 2nd ed 2015; 594- 605. Franco JS, Molano-González N, Rodríguez-Jiménez M, et al. Thecoexistence of antiphospholipid syndrome andsystemiclupuserythematosus in Colombians.PLoSOne. 2014 Oct 24;9(10):e110242. doi: 10.1371/journal.pone.0110242. eCollection 2014.
  4. Reeves WH, Xu Y, Zhuang H, Li Y,Yang L. Origins of antinuclearantibodies. In: Lahita RG, Tsokos G, Buyon JP, KoikeT,editors. Systemiclupuserythematosus. 5th edLondon: 2011; 213-33.
  5. Urowitz MB, Tselios K.Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus.CurrRheumatol Rev. 2017 Jul 4. doi: 10.2174/1573397113666170704 102444. Nesher G, Ilany J, Rosenmann D, Abraham AS.Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment.Semin Arthritis Rheum. 1997;27(1):27-35.